Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

12 May 2017

• By Sukaina Virji

The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?

Inchworms — Does Roche's failure indicate need for route change for IO in bladder cancer? • Source: Shutterstock

Roche's difficulties in confirming Tecentriq's efficacy in second line bladder cancer will likely have sent a shiver of unease through its competitors, rather than a cheer. (Also see "Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial" - Scrip, 10 May, 2017.)

Tecentriq (atezolizumab) is one of five similar products on or close to market for the same indication. Could this be...